JP2012502064A - 酸化還元活性治療剤を用いての広汎性発達障害の処置 - Google Patents

酸化還元活性治療剤を用いての広汎性発達障害の処置 Download PDF

Info

Publication number
JP2012502064A
JP2012502064A JP2011526277A JP2011526277A JP2012502064A JP 2012502064 A JP2012502064 A JP 2012502064A JP 2011526277 A JP2011526277 A JP 2011526277A JP 2011526277 A JP2011526277 A JP 2011526277A JP 2012502064 A JP2012502064 A JP 2012502064A
Authority
JP
Japan
Prior art keywords
formula
iiic
disorder
diene
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011526277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502064A5 (enExample
Inventor
ガイ エム． ミラー，
ビクトリア キーフェッツ，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012502064A publication Critical patent/JP2012502064A/ja
Publication of JP2012502064A5 publication Critical patent/JP2012502064A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Pediatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011526277A 2008-09-10 2009-09-08 酸化還元活性治療剤を用いての広汎性発達障害の処置 Withdrawn JP2012502064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19169608P 2008-09-10 2008-09-10
US61/191,696 2008-09-10
PCT/US2009/056254 WO2010030607A1 (en) 2008-09-10 2009-09-08 Treatment of pervasive developmental disorders with redox-active therapeutics

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015055908A Division JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055909A Division JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置

Publications (2)

Publication Number Publication Date
JP2012502064A true JP2012502064A (ja) 2012-01-26
JP2012502064A5 JP2012502064A5 (enExample) 2012-10-25

Family

ID=41226405

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011526277A Withdrawn JP2012502064A (ja) 2008-09-10 2009-09-08 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055909A Withdrawn JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055908A Active JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015215902A Pending JP2016020399A (ja) 2008-09-10 2015-11-02 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2017076681A Withdrawn JP2017122125A (ja) 2008-09-10 2017-04-07 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2018116995A Pending JP2018162281A (ja) 2008-09-10 2018-06-20 酸化還元活性治療剤を用いての広汎性発達障害の処置

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015055909A Withdrawn JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055908A Active JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015215902A Pending JP2016020399A (ja) 2008-09-10 2015-11-02 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2017076681A Withdrawn JP2017122125A (ja) 2008-09-10 2017-04-07 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2018116995A Pending JP2018162281A (ja) 2008-09-10 2018-06-20 酸化還元活性治療剤を用いての広汎性発達障害の処置

Country Status (8)

Country Link
US (7) US8314153B2 (enExample)
EP (2) EP3827815B1 (enExample)
JP (6) JP2012502064A (enExample)
BR (1) BRPI0918139B1 (enExample)
CA (1) CA2736250C (enExample)
LT (1) LT3827815T (enExample)
MX (2) MX2011002318A (enExample)
WO (1) WO2010030607A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161510A (ja) * 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP3827815B1 (en) * 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
TR201819154T4 (tr) 2008-10-28 2019-01-21 Bioelectron Tech Corp Alfa-tokotrienol kuinone ve ara ürünlerini içeren bileşim.
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
CA2772294C (en) * 2009-08-26 2018-08-21 Guy M. Miller Methods for the prevention and treatment of cerebral ischemia
JP2013523816A (ja) * 2010-04-06 2013-06-17 エジソン ファーマシューティカルズ， インコーポレイテッド 毛細血管拡張性運動失調症の治療
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US8828453B2 (en) * 2010-04-29 2014-09-09 Betul Hatipoglu Herbal-based compositions for alleviating symptoms associated with autism
MX2013001469A (es) * 2010-08-06 2013-05-14 Edison Pharmaceuticals Inc Tratamiento de enfermedades mitocondriales con naftoquinonas
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
AU2012332574B2 (en) * 2011-10-31 2015-11-05 The Johns Hopkins University Methods and compositions for treatment of autism
CA2883882A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP3233786B1 (en) 2014-12-16 2022-03-16 PTC Therapeutics, Inc. Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
KR20220078644A (ko) 2019-10-04 2022-06-10 스텔스 바이오테라퓨틱스 인코포레이티드 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체
WO2021077034A1 (en) 2019-10-18 2021-04-22 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
JP2023520462A (ja) 2020-04-03 2023-05-17 ステルス バイオセラピューティクス インコーポレイテッド フリードライヒ運動失調症を含むミトコンドリア病の予防および／または治療のための組成物および方法
CA3222132A1 (en) 2021-06-10 2022-12-15 Stealth Biotherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물
WO2024050725A1 (en) 2022-09-07 2024-03-14 Ptc Therapeutics, Inc. Methods of producing 2, 3, 5, 6-alkyl-1, 4-benzoquinones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856414A (en) 1958-10-14 Oxidation of alpha-tocopherol
FR5531E (fr) 1905-03-02 1906-05-02 Gaston Levy Lajeunesse Perfectionnements aux moteurs à explosions
US2398418A (en) 1943-08-27 1946-04-16 Louis F Fieser Introduction of organic radicals into quinones
FR1201200A (fr) 1958-08-08 1959-12-29 Sogespar S A Procédé de fabrication de l'alpha tocophéryl-quinone
US3071512A (en) 1959-01-26 1963-01-01 Sogespar S A New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone
US3406188A (en) * 1964-03-27 1968-10-15 Sun Oil Co Preparation of alpha-tocopherylquinone
FR5531M (enExample) 1966-02-08 1967-11-13
FR1536576A (fr) 1967-08-29 1968-08-16 Eastman Kodak Co Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols
US3849453A (en) 1970-03-17 1974-11-19 Takeda Chemical Industries Ltd Quinone derivatives
US3705239A (en) 1970-10-16 1972-12-05 Roy B Gregory Pain removing compositions and methods
UST917001I4 (en) 1971-12-02 1973-12-04 Defensive publication
JPS4875564A (enExample) 1972-01-08 1973-10-11
JPS4988862A (enExample) 1972-12-29 1974-08-24
JPS5245698B2 (enExample) 1973-04-06 1977-11-17
US3957836A (en) 1973-07-02 1976-05-18 Takeda Chemical Industries, Ltd. Quinone derivatives
US3909376A (en) 1974-12-04 1975-09-30 Basf Ag Electrolytic manufacture of alkyl-substituted hydroquinones
JPS52111576A (en) 1976-03-15 1977-09-19 Teijin Ltd Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol
JPS5938203B2 (ja) 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US4153614A (en) 1978-05-12 1979-05-08 Hoffmann-La Roche Inc. Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein
US4201879A (en) 1977-05-16 1980-05-06 Hoffmann-La Roche Inc. Hydroquinones
LU77344A1 (enExample) 1977-05-16 1979-01-19
US4185154A (en) 1977-05-17 1980-01-22 Hoffmann-La Roche, Inc. Synthesis of vitamin E
US4243598A (en) 1977-05-17 1981-01-06 Hoffmann-La Roche Inc. Synthesis of vitamin E
US4127608A (en) 1977-05-17 1978-11-28 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4201726A (en) 1977-05-17 1980-05-06 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4310465A (en) 1977-05-17 1982-01-12 Hoffmann-La Roche Inc. Synthesis of vitamin E and quinone intermediates
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS56147746A (en) 1980-04-15 1981-11-16 Takeda Chem Ind Ltd Quinones and their preparation
JPS567734A (en) 1979-06-28 1981-01-27 Takeda Chem Ind Ltd Preparation of quinone derivative
JPS567737A (en) 1979-07-02 1981-01-27 Takeda Chem Ind Ltd Physiologically active quinone and its preparation
JPS5697223A (en) 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
JPS56140943U (enExample) 1980-03-19 1981-10-24
JPH0193554A (ja) 1980-04-07 1989-04-12 Takeda Chem Ind Ltd 有機化合物
JPS56140943A (en) 1980-04-07 1981-11-04 Takeda Chem Ind Ltd Preparation of organic compound
US4393075A (en) 1980-04-14 1983-07-12 Takeda Chemical Industries, Ltd. Quinone compounds and their use in suppressing the production of SRS-A in mammals
JPS5750935Y2 (enExample) 1980-06-03 1982-11-06
JPS5750935A (en) 1980-09-12 1982-03-25 Otsuka Pharmaceut Co Ltd 1,4-benzoquinone derivative
JPS57131735A (en) 1981-02-09 1982-08-14 Takeda Chem Ind Ltd Preparation of quinones
JPS6140236Y2 (enExample) 1981-04-03 1986-11-17
JPS57183782A (en) 1981-04-30 1982-11-12 Sumitomo Chem Co Ltd Preparation of coumarone compound
JPS5818374A (ja) 1981-07-27 1983-02-02 Nitsusui Seiyaku Kk エイコサペンタエン酸トコフエロ−ルエステル
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS5883698U (ja) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 熱交換器
JPS6028919Y2 (ja) 1981-12-28 1985-09-02 松下電器産業株式会社 太陽熱集熱装置
JPS58193689A (ja) 1982-05-10 1983-11-11 Shiseido Co Ltd テストステロン−５α−レダクタ−ゼ阻害剤
JPS58193689U (ja) 1982-06-18 1983-12-23 三菱電機株式会社 電子部材実装装置
DK449983A (da) 1982-10-27 1984-04-28 Hoffmann La Roche Fremgangsmaade til fremstilling af optiske aktive forbindelser
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
JPS59163316A (ja) 1983-03-08 1984-09-14 Eisai Co Ltd けいれんの治療・予防剤
JPS6028919A (ja) 1983-07-28 1985-02-14 Shiseido Co Ltd 皮膚外用剤
EP0134198A1 (de) 1983-08-10 1985-03-13 Ciba-Geigy Ag Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden
JPS60197621A (ja) 1984-03-19 1985-10-07 Hohnen Oil Co Ltd コレステロ−ル低下剤
MX9203040A (es) 1984-08-01 1992-07-31 Takeda Chemical Industries Ltd Derivados de quinona y composicion farmaceutica que los contiene.
US5304658A (en) 1984-08-01 1994-04-19 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
US4592867A (en) 1984-10-19 1986-06-03 Energy Conversion Devices, Inc. Synthesis method for reductant precursor
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
DE3484473D1 (de) 1984-12-06 1991-05-23 Kuraray Co Chroman-verbindungen und deren herstellung.
JPH0511467Y2 (enExample) 1985-03-19 1993-03-22
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5057514A (en) 1987-02-03 1991-10-15 Suntory Limited Compounds effective as cerebral schemia treating agents
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5292768A (en) 1987-12-22 1994-03-08 Suntory Limited Compound effective as cerebral insufficiency improver
US5179092A (en) 1987-12-22 1993-01-12 Suntory Limited Compound effective as cerebral insufficiency improver
DK36389A (da) 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
JPH01209445A (ja) 1988-02-17 1989-08-23 Fuji Photo Film Co Ltd 放射線感応性材料
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
JPH029875A (ja) 1988-03-16 1990-01-12 Bio Ind Kyokai トコフェロール及びトコトリエノールの製造方法
DE3818696C1 (en) 1988-06-01 1989-03-30 Ems-Inventa Ag, Zuerich, Ch Process for the preparation of hydroquinone and its alkyl derivatives
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
JPH08768B2 (ja) 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
FI102273B1 (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
WO1993009777A1 (en) 1991-11-22 1993-05-27 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
EP0459148B1 (en) 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
JP3086284B2 (ja) 1991-07-05 2000-09-11 京セラミタ株式会社 電子写真感光体
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
EP0560568A3 (en) 1992-03-13 1994-06-29 Takeda Chemical Industries Ltd Hydroquinone derivatives and intermediates for production thereof
ES2224098T3 (es) 1992-05-28 2005-03-01 Centre For Molecular Biology And Medicine, Derivados de quinona para aumentar la bioenergia celular.
CN1093360A (zh) 1992-10-02 1994-10-12 武田药品工业株式会社 2-o-烷基抗坏血酸的锂盐
DE69420776T2 (de) 1993-06-18 2000-05-18 Takeda Chemical Industries, Ltd. Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
US5600029A (en) 1994-03-09 1997-02-04 Takeda Chemical Industries, Ltd. Process for producing DL-tocopherols and intermediates therefor
JP2742333B2 (ja) 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US6133278A (en) 1994-08-12 2000-10-17 Takeda Chemical Industries, Ltd. Use of quinone and hydroquinone derivatives for the treatment of cachexia
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
JPH0892151A (ja) 1994-09-29 1996-04-09 Sagami Chem Res Center アリルキノンの製造方法
US5547827A (en) 1994-12-22 1996-08-20 Eastman Kodak Company Iodochloride emulsions containing quinones having high sensitivity and low fog
EP0719552A3 (en) 1994-12-26 1997-08-20 Takeda Chemical Industries Ltd Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis
NZ298074A (en) 1994-12-28 2001-01-26 Janssen Pharmaceutica Nv Use of alpha,alpha'-iminobis(methylene)bis[2-chromanmethanol] derivatives for treating degenerative diseases of the vascular or nervous systems
US20030134028A1 (en) 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
AU6709896A (en) 1995-08-21 1997-03-12 Takeda Chemical Industries Ltd. Quinone compound, its production and use
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CA2220024C (en) 1996-03-25 2002-06-25 Alcon Laboratories, Inc. Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
WO1998002149A2 (en) 1996-07-11 1998-01-22 Takeda Chemical Industries, Ltd. Use of idebenone and analogues against beta amyloid induced cytotoxicity
FR2753098B1 (fr) 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
GB9702310D0 (en) 1997-02-05 1997-03-26 Univ Hertfordshire Invention
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
AU746369B2 (en) 1997-11-17 2002-04-18 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
BR9908141A (pt) 1998-01-29 2000-11-28 Eastman Chem Co Processo para separar um tocol de uma mistura de tocol
US5969133A (en) 1998-05-22 1999-10-19 Shiongi Bioresearch Corp. Bioreductive cytotoxic agents
US6433199B1 (en) 1998-05-22 2002-08-13 Shionogi Bioresearch Corporation Quinone derivatives
WO2000006550A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6187811B1 (en) 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6562372B1 (en) 1998-11-06 2003-05-13 Fuji Chemical Industry Co., Ltd. Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form
WO2005019233A1 (en) 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
JP2000202297A (ja) 1999-01-20 2000-07-25 Chemiprokasei Kaisha Ltd 新規な酸化反応用触媒およびそれを用いたｐ―ベンゾキノン類の製造方法
KR100879559B1 (ko) 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE19916801A1 (de) 1999-04-14 2000-11-02 Bosch Gmbh Robert Spritzdüse für eine Scheibenwaschanlage
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6346544B2 (en) 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
WO2001092215A2 (en) 2000-06-02 2001-12-06 Us Health Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US6545184B1 (en) 2000-08-15 2003-04-08 The Regents Of The University Of California Practical, cost-effective synthesis of COQ10
US20030206972A1 (en) 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
PL212952B1 (pl) 2000-10-26 2012-12-31 Fournier Lab Ireland Ltd Kompozycja farmaceutyczna zawierajaca fenofibrat i koenzym Q₁₀ oraz jej zastosowanie
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
WO2002043507A2 (en) 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
AU2002239748A1 (en) 2000-12-15 2002-06-24 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6764768B2 (en) 2001-02-28 2004-07-20 Arch Development Corporation Controlled release composition
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
JP2003064017A (ja) 2001-06-12 2003-03-05 Hokko Chem Ind Co Ltd オキシスチレン誘導体の蒸留方法
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
MXPA04001555A (es) 2001-08-21 2004-10-27 Galileo Pharmaceuticals Inc Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
CA2357053A1 (en) 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
JP2003137716A (ja) 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
WO2003043570A2 (en) 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) * 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
US7327800B2 (en) 2002-05-24 2008-02-05 Vecima Networks Inc. System and method for data detection in wireless communication systems
ATE328283T1 (de) 2002-07-01 2006-06-15 Santhera Pharmaceuticals Ch Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
US6953331B2 (en) 2002-08-30 2005-10-11 Extreme Components L.P. Positioning device with bearing mechanism
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
AU2004210013A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005000357A2 (en) 2003-06-25 2005-01-06 Charles Erwin Chemical combination and method for increasing delivery of coenzyme q 10
KR20060113651A (ko) 2003-08-08 2006-11-02 더 오하이오 스테이트 유니버시티 리서치 파운데이션 토코트리에놀의 보호 용도 및 치료 용도
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2005035490A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS
EP1718163A1 (en) 2004-02-23 2006-11-08 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7022441B2 (en) 2004-02-25 2006-04-04 Eastman Kodak Company Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging
JPWO2005084660A1 (ja) * 2004-03-05 2007-08-09 森重 文江 ミトコンドリア病予防と対策
WO2005090602A2 (en) 2004-03-18 2005-09-29 Sucampo Ag Method for diagnosing or predicting susceptibility to optic nueropathy
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US9271221B2 (en) 2004-06-22 2016-02-23 Apple Inc. Closed loop MIMO systems and methods
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
DE102004032837A1 (de) 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
CN101166706B (zh) 2005-02-28 2011-08-24 明治乳业株式会社 氢醌长链衍生物和/或苯氧基长链衍生物及含有它们的药品
EP1885353B1 (en) 2005-04-22 2015-01-07 Elizabeth Stuart Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
CN101212905B (zh) 2005-06-30 2013-01-09 协和化学工业株式会社 包含含有银的铝硫酸盐氢氧化物粒子的抗菌剂及其用途
WO2007037849A2 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
AU2006339607A1 (en) * 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
US20070208086A1 (en) 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP2000456A2 (en) 2006-03-30 2008-12-10 Idemitsu Kosan Co., Ltd. Material for organic electroluminescent device and organic electroluminescent device using the same
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
CA2674368A1 (en) 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EP2131679B1 (en) * 2007-02-22 2019-03-27 Children's Hospital & Research Center at Oakland Fatty acid formulations and methods of use thereof
MY162051A (en) 2007-05-24 2017-05-31 Loders Croklaan Bv Process for producing compositions comprising tocopherols and tocotrienols
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
AU2008346956A1 (en) 2008-01-07 2009-07-16 Centocor, Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111543A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
EP2303309A2 (en) 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
EP3827815B1 (en) 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8722728B2 (en) 2008-10-09 2014-05-13 Ramscor, Inc. Composition and method for treating dry eye syndrome
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
TR201819154T4 (tr) 2008-10-28 2019-01-21 Bioelectron Tech Corp Alfa-tokotrienol kuinone ve ara ürünlerini içeren bileşim.
BRPI1015006A2 (pt) 2009-04-28 2019-09-24 Ampere Life Sciences Inc uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2010126909A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
JP2012531411A (ja) * 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
CA2772294C (en) 2009-08-26 2018-08-21 Guy M. Miller Methods for the prevention and treatment of cerebral ischemia
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011112679A1 (en) 2010-03-09 2011-09-15 Penwest Pharmaceuticals Co. Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
JP2013523816A (ja) 2010-04-06 2013-06-17 エジソン ファーマシューティカルズ， インコーポレイテッド 毛細血管拡張性運動失調症の治療
AU2011245384C1 (en) 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
MX2013001469A (es) 2010-08-06 2013-05-14 Edison Pharmaceuticals Inc Tratamiento de enfermedades mitocondriales con naftoquinonas
JP2013538799A (ja) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
EP2729004B1 (en) 2011-07-06 2020-03-25 PTC Therapeutics, Inc. Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883882A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
CA2902506C (en) 2013-03-08 2024-11-19 Unilever Global Ip Limited Resorcinol compounds for dermatological use
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2014194292A1 (en) 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US20190241497A1 (en) 2016-10-28 2019-08-08 Andrew W. Hinman Methods for analyzing p-hydroquinone levels and ratios

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013057682; Ｐａｔｈｏｐｈｙｓｉｏｌｏｇｙ １３, 2006, ｐ．１７１-１８１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161510A (ja) * 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン

Also Published As

Publication number Publication date
MX363223B (es) 2019-03-15
MX2011002318A (es) 2011-05-10
BRPI0918139A2 (pt) 2015-12-01
BRPI0918139B1 (pt) 2024-04-30
US20170157065A1 (en) 2017-06-08
JP6259410B2 (ja) 2018-01-10
EP3827815A1 (en) 2021-06-02
US20100063161A1 (en) 2010-03-11
JP2015110674A (ja) 2015-06-18
EP2344142B1 (en) 2024-06-26
JP2018162281A (ja) 2018-10-18
EP2344142A1 (en) 2011-07-20
US8314153B2 (en) 2012-11-20
CA2736250A1 (en) 2010-03-18
US20210128494A1 (en) 2021-05-06
US10105325B2 (en) 2018-10-23
LT3827815T (lt) 2023-10-10
US9399612B2 (en) 2016-07-26
US8969420B2 (en) 2015-03-03
JP2017122125A (ja) 2017-07-13
US10736857B2 (en) 2020-08-11
WO2010030607A1 (en) 2010-03-18
US20190083419A1 (en) 2019-03-21
US20150239818A1 (en) 2015-08-27
US20140206772A1 (en) 2014-07-24
US8653144B2 (en) 2014-02-18
EP3827815B1 (en) 2023-09-06
US20130053450A1 (en) 2013-02-28
JP2015120748A (ja) 2015-07-02
JP2016020399A (ja) 2016-02-04
CA2736250C (en) 2016-12-20

Similar Documents

Publication Publication Date Title
JP6259410B2 (ja) 酸化還元活性治療剤を用いての広汎性発達障害の処置
US20120122969A1 (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
Virdis et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension
EP2555765A1 (en) Treatment of ataxia telangiectasia
Ryan et al. Dermatologic conditions in Down syndrome
Luo et al. The dual‐functional memantine nitrate MN‐08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models
JP2007501846A (ja) トコトリエノールの予防的使用および治療的使用
EP2808023A1 (en) New drug for the treatment and/or prevention of depressive disorders
HK40052915A (en) Treatment of pervasive developmental disorders with redox-active therapeutics
HK40052915B (en) Treatment of pervasive developmental disorders with redox-active therapeutics
Schuck et al. cis-4-decenoic acid provokes mitochondrial bioenergetic dysfunction in rat brain
HK1185017A (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
HK1184693A (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
Ikeda Biomarkers of oxidative injury in stroke patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150319

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150330